3snb: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:3snb.jpg|left|200px]] | |||
The | <!-- | ||
The line below this paragraph, containing "STRUCTURE_3snb", creates the "Structure Box" on the page. | |||
You may change the PDB parameter (which sets the PDB file loaded into the applet) | |||
or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |||
or leave the SCENE parameter empty for the default display. | |||
--> | |||
{{STRUCTURE_3snb| PDB=3snb | SCENE= }} | |||
===Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease=== | |||
<!-- | |||
The line below this paragraph, {{ABSTRACT_PUBMED_21854807}}, adds the Publication Abstract to the page | |||
(as it appears on PubMed at http://www.pubmed.gov), where 21854807 is the PubMed ID number. | |||
--> | |||
{{ABSTRACT_PUBMED_21854807}} | |||
==About this Structure== | |||
[[3snb]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Sars_coronavirus Sars coronavirus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3SNB OCA]. | |||
==Reference== | |||
<ref group="xtra">PMID:021854807</ref><references group="xtra"/> | |||
[[Category: Sars coronavirus]] | |||
[[Category: Hilgenfeld, R.]] | |||
[[Category: Zhu, L.]] | |||
[[Category: 3c-like proteinase]] | |||
[[Category: Ac-dsfdq-h]] | |||
[[Category: Covalent bound]] | |||
[[Category: Hydrolase-hydrolase inhibitor complex]] | |||
[[Category: Protease]] | |||
Revision as of 06:08, 7 September 2011
Template:ABSTRACT PUBMED 21854807
About this Structure
3snb is a 2 chain structure with sequence from Sars coronavirus. Full crystallographic information is available from OCA.
Reference
- Zhu L, George S, Schmidt MF, Al-Gharabli SI, Rademann J, Hilgenfeld R. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease. Antiviral Res. 2011 Aug 11. PMID:21854807 doi:10.1016/j.antiviral.2011.08.001
